CMS To Expand Screening Coverage For HIV, HPV
This article was originally published in The Gray Sheet
Executive Summary
CMS took steps to expand coverage for two infectious diseases: a final decision memo to cover screening for human immunodeficiency virus irrespective of risk and a proposal to cover human papillomavirus screens in combination with Pap smears for women aged 30 to 65.
You may also be interested in...
Big Week For HPV Dx: FDA Finalizes Guidance, Task Force Supports Solo Testing
An important task force drafted new recommendations supporting human papillomavirus tests as a solo first-line screen for cervical cancer in some women, followed up by a US FDA final guidance document detailing for test-makers how to best ensure assays for the cervical cancer-causing virus are safe and accurate.
Roche’s HPV Test Approved As First-Line Cervical Cancer Screen
The firm’s cobas human papillomavirus test is the first to gain approved labeling as a primary screen. It could be a market advantage for Roche, but the company now needs to work with clinical guideline developers to put the approved indication into routine practice.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.